Louise Watson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Louise Watson has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Andrew J. Chetwynd
University of Liverpool
1 shared publication - Angela Midgley
Institute of Child Health, Alder Hey Children's NHS Foundation Trust, Liverpool University, Liverpool, UK
1 shared publication - Anirudh Rao
Department of Nephrology, Liverpool University Hospitals N.H.S. Foundation Trust, Liverpool L7 8XP, UK
1 shared publication - Brian F. Flanagan
Department of Women’s and Children’s Health, Institute of Translational Medicine, University of Liverpool, Alder Hey Children’s NHS Foundation Trust Hospital, Eaton Road, Liverpool L12 2AP, UK
1 shared publication - Elin Mitford Davies
UK’s Experimental Arthritis Treatment Centre for Children, University of Liverpool, Liverpool, United Kingdom
1 shared publication - Garry McDowell
Liverpool Centre for Cardiovascular Science at Liverpool John Moores University (LJMU), University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool L8 8TX, UK
1 shared publication
Latest Publications
- Open Access
- 20 August 2025
- Published by MDPI AG in Kidney and Dialysis
- Vol. 5 (3) , 39
Biomarkers Predicting Major Adverse Cardiovascular Events in End-Stage Kidney Disease: A Systematic Review
Background: Cardiovascular disease is the leading cause of death in chronic kidney disease populations. The risk of major adverse cardiovascular events (MACE) is greater than that of progression to end-stage kidney disease. An exponential increase in mortality risk is associated with declining kidney function. This study aimed to review the current landscape of traditional and novel blood biomarkers in predicting MACE in ESKD patients. Methods: The systematic review was registered on PROSPERO (CRD42024497403). Standard and extensive Cochrane search methods were used. The latest search date was July 2023. Participants were aged ≥18 years with end-stage kidney disease. Descriptive analysis was performed and data was presented in tabular form. The hazard ratio or odds ratio was presented for potential biomarkers discovered. Results: Overall, 14 studies (4965 participants) were included for analysis; 12 focused on participants requiring haemodialysis and 2 on haemodialysis and peritoneal dialysis. The biomarkers analysed were Troponin I (n = 3), Troponin T (n = 3), B-type natriuretic peptide (n = 2), N-Terminal Pro-Brain-Natriuretic Peptide (n = 7), soluble receptors for advanced glycation end products (n = 2), Galectin 3 (n = 4), and the serum-soluble suppression of tumorigenicity-2 (n = 2). Reported study outcomes included all-cause mortality (n = 11), MACE (n = 5), cardiac specific mortality (n = 6), sudden cardiac death (n = 2), and first cardiovascular event (n = 3). Conclusions: This review outlines the potential role of traditional and novel biomarkers in predicting MACE in end-stage kidney disease. Further larger-scale research is required to establish the validity of the study outcomes to develop new methods of cardiovascular risk prediction in this high-risk population.
- 20 August 2025
- Published by MDPI AG in Kidney and Dialysis
- Vol. 5 (3) , 39
Open AccessBiomarkers Predicting Major Adverse Cardiovascular Events in End-Stage Kidney Disease: A Systematic Review
Background: Cardiovascular disease is the leading cause of death in chronic kidney disease populations. The risk of major adverse cardiovascular events (MACE) is greater than that of progression to end-stage kidney disease. An exponential increase in mortality risk is associated with declining kidney function. This study aimed to review the current landscape of traditional and novel blood biomarkers in predicting MACE in ESKD patients. Methods: The systematic review was registered on PROSPERO (CRD42024497403). Standard and extensive Cochrane search methods were used. The latest search date was July 2023. Participants were aged ≥18 years with end-stage kidney disease. Descriptive analysis was performed and data was presented in tabular form. The hazard ratio or odds ratio was presented for potential biomarkers discovered. Results: Overall, 14 studies (4965 participants) were included for analysis; 12 focused on participants requiring haemodialysis and 2 on haemodialysis and peritoneal dialysis. The biomarkers analysed were Troponin I (n = 3), Troponin T (n = 3), B-type natriuretic peptide (n = 2), N-Terminal Pro-Brain-Natriuretic Peptide (n = 7), soluble receptors for advanced glycation end products (n = 2), Galectin 3 (n = 4), and the serum-soluble suppression of tumorigenicity-2 (n = 2). Reported study outcomes included all-cause mortality (n = 11), MACE (n = 5), cardiac specific mortality (n = 6), sudden cardiac death (n = 2), and first cardiovascular event (n = 3). Conclusions: This review outlines the potential role of traditional and novel biomarkers in predicting MACE in end-stage kidney disease. Further larger-scale research is required to establish the validity of the study outcomes to develop new methods of cardiovascular risk prediction in this high-risk population.
- Open Access
- 16 January 2014
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 12 (1) , 4
The pro-inflammatory potential of T cells in juvenile-onset systemic lupus erythematosus
T cells are important to systemic lupus erythematosus (SLE) disease progression. This study determined the pro-inflammatory potential of T cells within the rare condition juvenile-onset SLE (JSLE).
- 16 January 2014
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 12 (1) , 4
Open AccessThe pro-inflammatory potential of T cells in juvenile-onset systemic lupus erythematosus
T cells are important to systemic lupus erythematosus (SLE) disease progression. This study determined the pro-inflammatory potential of T cells within the rare condition juvenile-onset SLE (JSLE).